Bio-Serum Particles (BSPs) are nanoscale, biologically derived components prepared from a patient's own blood, typically ranging from 20–200 nm. BSPs contain a complex profile of proteins, lipids, and regulatory genetic material, including microRNAs (miRNAs) and messenger RNAs (mRNAs), which are involved in cellular communication processes.
In reproductive medicine, BSPs are designed to support local cellular signaling and tissue microenvironments, providing a cell-free, autologous biologic approach that can be integrated into advanced fertility care.
Bio-Serum Particles differ from stem cells in several key ways. Unlike stem cell therapy, which uses live cells, BSPs are completely cell-free. This means BSPs eliminate risks associated with live cell therapy while providing the regenerative and signaling benefits that support fertility outcomes.
Because BSPs are cell-free and derived from the patient's own blood, they are biologically compatible and do not trigger immune rejection, making them an ideal complement to assisted reproduction protocols.
Platelet-rich plasma (PRP) has been widely used across regenerative medicine as an autologous biologic approach. However, PRP preparations can vary significantly in composition, cellular content, platelet concentration, leukocyte burden, and downstream signaling activity, which may limit consistency across applications.
BSP Biologics has developed Bio-Serum Particles (BSPs) as a more refined, cell-free biologic platform derived from a patient's own blood. Rather than relying primarily on bulk platelet concentration, BSPs are processed through controlled, standardized methods designed to yield a defined profile of biologically active components, including proteins, lipids, regulatory RNAs, cytokines, and other signaling molecules involved in cellular communication and tissue microenvironment regulation.
This distinction is particularly important in reproductive medicine and women's health, where biologic signaling, tissue responsiveness, and microenvironment balance may be critical. BSPs are designed to provide a more characterized and quality-controlled preparation than conventional PRP, with analytical assessment that may include nanoparticle tracking analysis (NTA), flow cytometry, and molecular cargo profiling.
In contrast to many PRP protocols, BSP Biologics emphasizes standardized processing, minimal manipulation, sterility, and reproducibility within an FDA-conscious framework aligned with 21 CFR 1271 / 361 HCT/P regulatory principles. The result is a personalized, autologous, acellular biologic platform designed for integration into reproductive and gynecologic applications where consistency and biologic characterization are essential.
| Feature | Bio-Serum Particles (BSPs) | Platelet-Rich Plasma (PRP) |
|---|---|---|
| Source | Patient's blood | Patient's blood |
| Composition | Cell-free extracellular vesicles, proteins, RNAs | Platelets, growth factors, whole cells |
| Cell Content | Completely cell-free | Contains live platelets and cells |
| Processing | Minimally manipulated, standardized | Centrifugation-based concentration |
| Characterization | NTA, Flow cytometry, RNA/protein analysis | Limited standardization |
BSP therapy is designed within a framework that prioritizes safety, sterility, and regulatory alignment. Because BSPs are derived from a patient's own biologic material, they are intended to support biologic compatibility within autologous applications.
BSPs are processed using standardized, controlled methods to produce acellular, ready-to-use preparations without enzymatic modification or genetic manipulation. These processes are designed to align with FDA 21 CFR 1271 / 361 HCT/P regulatory principles.
As with any biologic approach, BSP therapy is being studied to further evaluate its safety and clinical profile. Use may not be appropriate in certain patient populations, including those with active systemic infections, known or suspected malignancies, uncontrolled autoimmune conditions, or during pregnancy.
The BSP process involves five main steps:
Our standardized, minimally manipulated protocols are designed to support consistency and quality, resulting in sterile, acellular preparations intended for clinical use.
To get started with BSP Biologics, simply reach out to us at info@bspbiologics.com. Our team will be happy to answer your questions, provide more information about our services, and guide you through the next steps.
You can also contact us at this email address to begin the process or to order your kits.
To get started with BSP Biologics, simply reach out to us. Our team will be happy to answer your questions, provide more information about our services, and guide you through the next steps.